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OVERVIEW — This background paper provides an overview of organized
programs that provide access to prescription drug products for uninsured
persons, with an emphasis on manufacturer-sponsored pharmacy assistance
programs (PAPs) and the federal 340B drug pricing program. It summa-
rizes the chief characteristics of these programs and reviews concerns re-
garding the reach and efficiency of these efforts. The paper begins with a
brief examination of the number of people who lack insurance coverage for
prescription drugs and discusses the influence of this gap in coverage on
health status. The paper also describes informal mechanisms providers fre-
quently use to help uninsured patients fill their prescriptions, such as sample
dispensing. The paper briefly explores the impact of Medicare Part D on
both manufacturer-sponsored PAPs and state pharmacy assistance programs
that have not traditionally focused on the under-65 uninsured population.
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The Prescription Drug Safety Net:
Access to Pharmaceuticals
for the Uninsured
One of the most prominent health care headlines of 2006 concerned the
implementation of the Part D prescription drug benefit, a voluntary pre-
scription drug benefit available to Medicare benficiaries. Although some
gaps remain, Part D has certainly strengthened the prescription drug
safety net for Medicare beneficiaries, particularly for the elderly and dis-
abled individuals who are eligible for low-income subsidies. A signifi-
cant number of beneficiaries who previously lacked insurance coverage
for prescription drugs now get coverage through Part D. One result of
these developments is the potential for policymakers to shift their focus
to the non-Medicare population lacking prescription drug coverage and
the safety net available to them.
When an uninsured person needs medical attention, he or she may go to a
community health center, a clinic, or a hospital emergency room to re-
ceive care regardless of ability to pay. If an uninsured person needs a pre-
scription, the facility might provide a few days’ supply to get things started.
But the local pharmacy will not fill an entire prescription for free. What
are the alternatives for this person?
For individuals who lack public or private health insurance to cover their
prescription drug needs, there are a number of resources available to help
provide access to drugs. Two important components of this “safety net” are
programs established by pharmaceutical manufacturers to make their drugs
available to those with low incomes and the federal government’s program
to offer drugs at a discounted price for safety net institutions, such as com-
munity heath centers and public hospitals. These two programs each make
available about $4 to $5 billion in drugs annually; together they are equiva-
lent to nearly 5 percent of total drug spending in the United States. Some
individuals also may be provided free drugs by physicians who dispense
the samples provided to them by manufacturers.
Individuals sometimes find these programs a vital lifeline that provides
critical drugs not available by any other means. But others may find these
programs cumbersome to use, either requiring extensive paperwork to es-
tablish eligibility or limiting their access to certain providers or certain drugs.
This background paper describes the various safety net programs for pre-
scription drugs as well as some of the issues involved in using them. The
primary focus is on programs designed to serve people without insurance
coverage for drugs, including the working uninsured, those who are poor
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but not eligible for coverage under Medicaid or other public programs,
and those whose insurance plans do not provide drug coverage. The pa-
per does not examine the role played by public programs in providing
drug coverage or the resources available to uninsured Americans that are
not focused specifically on prescription drugs.1
After a brief review of the target population for these safety net programs,
the paper examines programs created by pharmaceutical manufacturers
to provide their drugs to needy individuals, as well as the barriers to their
use and various efforts to improve access to these programs. It also dis-
cusses briefly the changes that have occurred in these programs as a result
the implementation of Medicare Part D. The next section looks at the fed-
eral program that helps clinics, hospitals, and other safety net providers
obtain drugs at discounted prices, thus strengthening their ability to get
needed drugs for the patients they serve. Individual physicians play a
role as well, and the next sections of the paper describe the use of drug
samples by physicians as well as the potential for physicians to prescribe
drugs more cost-effectively for those who lack coverage. Finally, the pa-
per discusses some considerations for policymakers who might want to
strengthen the safety net for drugs.
BACKGROUND: GAPS IN COVERAGE FOR
PRESCRIPTION DRUGS
Nearly one-fourth (24 percent) of adults aged 19 to 64 lacked insurance cover-
age for prescription drugs at some point in 2001, the most recent year for
which good data are available (Figure 1).2 Nearly two-thirds of those without
drug coverage did not have any kind of health insur-
ance; the rest were insured but lacked coverage for
prescription drugs. An earlier study found that a simi-
lar proportion (23 percent) of the non-Medicare popu-
lation lacked insurance coverage for prescription
drugs in 1996.3 According to the latter study, nearly
all workers covered by employer health plans and all
Medicaid beneficiaries had prescription drug cover-
age, whereas drug coverage was less universally in-
cluded in other forms of coverage, such as policies
purchased through the individual insurance market.
The 1996 survey data showed that near-poor indi-
viduals were the most likely to lack coverage for
drugs [36.5 percent of those with incomes between
100 and 200 percent of the federal poverty level
(FPL); for 2007 the FPL is $10,210 for a single per-
son, $13,690 for a family of two], but there were sig-
nificant numbers at different income levels. About
14 percent of those with incomes above 400 percent
of the FPL lacked coverage for drugs.4 Similarly, the
FIGURE 1
Distribution of Prescription Drug Benefits
Among Adults Aged 19 to 64, 2001
Source: Claudia L. Schur, Michelle M. Doty, and Marc L. Berk, “Lack of Pre-
scription Coverage Among the Under 65: A Symptom of Underinsurance,”
Issue Brief, Task Force on the Future of Health Insurance, The Commonwealth
Fund, February 2004; available at www.cmwf.org/usr_doc/Schur_under65.pdf.
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absence of coverage ranges across people with different health status. Those
in poor health in the 1996 survey were more likely than those in better
health to have drug coverage (84 percent versus the overall level of 77
percent), perhaps because they seek out private coverage sources or are
more likely to be eligible for (and enroll in) public sector coverage.5
The absence of drug coverage has clear consequences. Based on the 2001
survey, nonelderly adults without drug coverage were almost twice as
likely to report not filling a prescription due to cost (Figure 2). They are
also less likely to see a doctor when sick or to skip recommended tests or
follow-up care, possibly because they
know that filling a recommended pre-
scription will be difficult or impossible.6
Other studies provide additional evidence
that people skip their drugs when costs are
high. A 2001 Quebec study found that, after
imposition of higher cost sharing, patients
took fewer drugs identified by researchers
as “essential” and experienced an increased
use of emergency room visits and admis-
sions to hospitals or nursing homes. There
was also a decline in the use of “less essen-
tial” drugs, but this change was not associ-
ated with an increase in the use of other
health services.7 Another study of increased
cost sharing in two Medicare health main-
tenance organizations (HMOs) found lower
drug utilization but no consistent changes
in either medical care utilization (office visits, emergency room visits, home
health visits, and hospitalizations) or total medical care expenses.8
Similarly, several studies have addressed the impact of drug costs by look-
ing at the effect of capped drug benefits. Two studies of monthly limits on
prescriptions by Medicaid programs showed that reduced drug use resulted
in increased nursing home admissions and, for patients with schizophre-
nia, increased visits to community mental health centers, use of emergency
mental health services, and partial hospitalization (although no increase in
hospital admissions).9 About one-third of Medicare beneficiaries with chronic
illnesses who enrolled in eight managed care plans with a capped drug
benefit reported not filling a prescription or reducing the prescribed dosage
because of their out-of-pocket costs. The result was under-use of needed
medications, especially for those with lower incomes or poorer health.10
A further illustration of what happens to people without access to drug
coverage comes from a study of Oregon residents who were enrolled in the
state’s Medically Needy program as of January 2003 but lost access to those
benefits because of shortfalls in the state budget. Although most were eli-
gible for Medicare coverage for medical benefits, the state program had
FIGURE 2
Percentage of Adults Aged 19 to 64 Who Did Not Fill
a Prescription Due to Cost, 2001, by Insurance Category
Source: Schur, Doty, and Berk, “Lack of Prescription Coverage Among the Under 65.”
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been paying for their prescription drugs and fee-for-service Medicare was
not yet offering such coverage. On average, the individuals studied used
the same number of prescriptions as when they were in the Medically Needy
program, but half reported that they were prescribed drugs they were not
taking because of cost. One-third of those surveyed also indicated that they
switched to a similar, but lower-cost drug; nearly half said they were pay-
ing out of pocket (46 percent); and some reported using drug company as-
sistance programs (26 percent) or getting free samples from their doctors (7
percent). Respondents also reported cutting back their food budget, skip-
ping or delaying bills, or borrowing money to pay for prescribed drugs.11
MANUFACTURER-SPONSORED
PRESCRIPTION ASSISTANCE PROGRAMS
When an uninsured person needs help filling prescriptions and cannot af-
ford the cost of these drugs, he or she may seek to obtain drugs free of
charge from pharmaceutical manufacturers. Many manufacturers have es-
tablished prescription assistance programs (PAPs) to provide certain low-
income people the ability to obtain drugs they might not be able to purchase
without assistance. There are about 180 manufacturer-sponsored programs,
according to the Partnership for Prescription Assistance, a program launched
in 2005 by the Pharmaceutical Research and Manufacturers of America
(PhRMA) to provide outreach and simplified access to these programs. Some
programs have been around for as long as 50 years, but they have taken on
different forms over the years. In 2005, manufacturer PAPs donated drugs
with an estimated wholesale value of about $5 billion.12
In general, these manufacturer-sponsored programs are designed as tem-
porary programs to be used as a last resort for people who have exhausted
all public program options, have no private insurance, and have low in-
comes. Most major manufacturers offer programs, although they may not
make all their drugs available. Resource services that offer consolidated
lists of the drugs available across plans suggest that at least 1,500 drugs
are available through these programs.13 A November 2000 report by the
U.S. Government Accountability Office (GAO; then known as the General
Accounting Office) found that all but 2 from a list of 50 commonly pre-
scribed brand-name drugs for elderly patients were available through
manufacturer PAPs.14 As described below, two programs have been
launched to make some commonly prescribed generic drugs available. A
service that includes these generics in its list suggests that a total of about
3,000 drugs can be obtained through PAPs.
Eligibility and application requirements vary across the different programs,
but typically they require that applicants be U.S. citizens and have incomes
below 200 percent of the FPL.15 Generally, anyone with prescription drug
coverage is not eligible (although exceptions for some Medicare benefi-
ciaries with Part D coverage are discussed below), and some companies
require that applicants have no health insurance of any kind.16
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There appears to be no reliable count of how many people have obtained
drugs through these programs. According to the Partnership, more than 3
million people have received help through the Partnership in nearly two
years, but this number includes those who received advice but did not
obtain drugs through the PAPs.17 And other patients obtain help from PAPs
without going through the Partnership. PhRMA reports that in 2005 an
estimated 36 million prescriptions (with a wholesale value of about $5
billion) were filled through manufacturer programs.18
In some programs, the physician must apply on behalf of the patient. In
others, a patient advocate or patient is allowed to apply, though even these
typically require information about the prescribing physician and often
the physician’s signature.19 Some physicians’ offices that prescribe high-
cost drugs have a staff person who seeks out assistance programs for which
a particular patient might be eligible. This approach is especially used by
oncology practices and others who regularly prescribe expensive physician-
administered drugs. In addition, PAPs are often used by certain safety net
providers, such as free clinics that do not qualify for receiving low-cost drugs
through the federal 340B program (described below).
Under the PAPs, medications are usually shipped to a clinic or doctor’s
office, rather than directly to the patient; under some plans, patients re-
ceive a voucher for the drugs to be redeemed at a pharmacy. In most cases,
there is no charge to the patient. But some programs charge the patient co-
payments, dispensing fees, or shipping and handling fees.
Issues Raised by Manufacturer Programs
Learning about manufacturer programs may be the first barrier to their
use by uninsured patients. Indigent people are least likely to have access
to a primary care physician or to know what medications they need. When
they do have a prescription for a costly drug, they may not know that
manufacturer PAPs exist. As a result, the people who need these programs
the most may have the hardest time accessing them. Furthermore, they
may discover that each of their expensive drugs is made by a different
manufacturer and that each requires a separate application, often with
different information required.
Manufacturer sales representatives typically inform physicians about PAPs,
although sometimes physicians have to request the information.20 PhRMA’s
Partnership (see “Points of Access,” below) has raised the visibility of these
programs in recent years with a national outreach program that includes
celebrity spokespersons, toll-free telephone lines, television advertisements,
partnerships with various organizations, and two “Help is Here Express”
buses traveling around the country.21
One significant challenge faced by users of manufacturer PAPs is the com-
plexity of the application process. The process often becomes a greater
burden to staff at physicians’ offices or clinics than to patients, because
There is no reliable
count of how many
people have obtained
drugs through PAPs,
but PhRMA estimates
that about 36 million
prescriptions, worth
about $5 billion, were
donated in 2005.
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staff are often responsible for completing the applications. Physicians’ of-
fices may choose to take on this task because their patients may have no
other means of obtaining needed medications, but they report that it can
be a drain on office resources. Physicians also point out that they are not
reimbursed for doing paperwork, although there is a billing code for “spe-
cial reports such as insurance forms, more than the information conveyed
in the usual medical communications or standard reporting forms.”22 Ac-
cording to one study that surveyed clinics in several states, clinic staff
spent an average of 111 hours per month (12 hours for pharmacists, 20
hours for physicians, and 79 hours for other staff) in processing applica-
tions. In fact, two-thirds of clinics that did not use the manufacturer PAPs
cited the fact that they are “too time-consuming and complex.”23
Although the time demands of processing applications represent a real
cost for providers, software or other management resources are available
to help the processing of applications. Several vendors offer the ability to
process applications electronically, and two of the vendors indicate that
they can offer electronic applications for nearly two-thirds of the pro-
grams.24 Although the cost of these resources (as much as $5,000 annually)
can stress already tight budgets for safety net providers, well-designed
management resources may be cost effective because they reduce staff
time spent on such tasks.25
The time demands are complicated by several factors: the requirement to
submit new applications after a set period of time or dosage change, the
need in many cases to submit separate applications for different medica-
tions, and the possibility that application requirements might change over
time. The GAO study found, for example, that some programs required
separate applications even when a patient sought to get more than one
drug from the same program. In addition, while prescription refills could
be obtained, programs sometimes required patients to reapply.26 At the
very least, patients requiring medications from more than one company
needed to complete separate applications for each, though some new ini-
tiatives (see “Innovative Ways,” below) allow a single application.
Eligibility requirements reflect the efforts of sponsoring manufacturers to
target a particular population for the drugs they are giving away. But one
result is that documentation requirements to verify patient eligibility can be
complex and difficult to achieve. Some programs have required that infor-
mation on the patient’s income be documented, for example, by a copy of a
tax return. Others have required documentation stating that a patient is not
eligible for assistance from public programs such as Medicaid.27 These types
of documents can be difficult for some patients to get or retain.
Because most programs distribute drugs to approved patients through
health care providers, some providers report that this requires them to
maintain proper storage and inventory management for the drugs. As a
result, they often prefer programs that provide coupons or vouchers al-
lowing the patients to obtain the drugs directly from a pharmacy. These
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coupon or voucher systems also may avoid the time lag between estab-
lishing eligibility and actual delivery of the drug. Absent such a system,
delays can be significant. The GAO found that while many programs could
deliver drugs in less than seven days, one program reported that it could
take up to 42 days between approval of the application and shipment of the
drug. Because of this delivery lag, clinics typically preferred to use PAPs
without voucher systems only for chronic, rather than acute, conditions.28
Of course, many of the expensive drugs sought through the PAPs are ad-
ministered by physicians via injection or infusion and so providers are
accustomed to dealing with inventory and storage issues. For example,
oncologists who offer chemotherapy in the office setting typically main-
tain an inventory of drugs so that they can make adjustments to the pre-
scribed therapy on the day of treatment.
In the previously described survey of Oregon residents who lost drug cov-
erage when a state program was cut back, 67 percent of respondents said
they were aware of manufacturer PAPs, and 45 percent were using them
(about half said these programs were their primary source for drugs). Most
reported getting help with the paperwork, usually from a doctor’s office
or clinic. Despite the fact that a significant number of this group were
getting help from PAPs, over half of these patients found the programs
hard to use and were not confident of getting continued help from them.
They also indicated that they were obtaining only some of their prescrip-
tions filled through these programs, usually because not all were offered
by a PAP. Of those who had never applied to a PAP, some were simply
unaware of the programs or felt it was too much hassle, while others knew
that the programs did not cover their particular drugs.29
Innovative Ways to Streamline Access
The challenges faced in completing applications for manufacturer PAPs
have led safety net providers to seek ways to streamline access to these
programs. In some cases, this may simply mean devoting adequate re-
sources to the task. One health center found that doing so had a payoff:
dedicating one full-time staff member to handling program applications
generated more than $300,000 worth of free drugs in one year. In Cleve-
land, a county hospital put automated prompts into its electronic medical
record system to assist physicians in obtaining donated drugs. And a county
hospital in Indianapolis was able to arrange for a system of bulk replace-
ment from drug manufacturers in cases where patients were deemed eli-
gible for the program instead of applying individually for each patient.
The result was $3 million worth of free drugs, double the level of the two
previous years.30 In other cases, a physician’s office may recruit a volunteer
patient advocate who works with patients to identify programs that may
help them, assists them with the applications, and helps track delivery of
the drugs and the process for getting renewals.31 When volunteer resources
are not available, some private physician practices have experimented with
Safety net providers
have been seeking
ways to streamline
access to PAPs.
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charging patients a modest fee ($5 to $10) for every application to defray
the costs of assisting them in accessing free drugs.32
Because of the complexities and challenges inherent to obtaining drugs
through manufacturer PAPs, some innovative programs have emerged to
simplify access for clinics and other safety net providers. Some programs
are narrowly focused on making drugs available to existing clinics or other
safety net providers, while others are more fully integrated with provid-
ing access to other health care services.
■ The Rx Partnership was launched in 2003 with the help of the Virginia
Health Care Foundation to make free prescription drugs available to par-
ticipating free clinics and community health centers in Virginia. The pro-
gram, using a combination of state funding and private grants, solicits
free medications in bulk from manufacturers and arranges for their distri-
bution directly to free clinics and community health centers. Participating
clinics must operate a licensed pharmacy and pay a $250 one-time fee to
join the partnership. The advantage of this approach is that patients can
fill their prescriptions immediately and avoid the wait that is common in
PAPs; availability of medications, however, is limited to the drugs that
participating manufacturers choose to make available. Nearly $2 million
in drugs was distributed in the first year of operation.33
■ MEDBANK, a nonprofit organization based in Maryland, has connected
patients to manufacturer PAPs since 2001. In its first five years of op-
eration, it helped nearly 35,000 patients fill more than 400,000 prescrip-
tions with drugs worth over $100 million. To be eligible, applicants
must have a monthly income above $926.01 for one person ($1,070.01
for a household of two) and no source of drug coverage. Those with
lower incomes are referred to state programs. Started with a founda-
tion grant, MEDBANK now gets one-third of its funding from the state,
with the rest coming from grants and donations. Some drugs are made
available through a bulk-distribution pharmacy, which distributes
drugs from four participating manufacturers to physicians. Other medi-
cations are arranged through manufacturer PAPs, with MEDBANK
automating the application process and handling application renew-
als for physicians. The program has been replicated in New Mexico.34
■ South Carolina’s Communicare program involves a network of physi-
cians who see patients in their offices at no charge. In order to make
sure patients could get the drugs they need, the physicians negotiated
arrangements with some manufacturers to donate free drugs. Estab-
lished in 1993, a network of 2,500 physicians serves about 15,000 pa-
tients across the state. Communicare now operates a central pharmacy
that dispenses donated drugs by mail to patients’ homes, physicians’
offices, or a network of free clinics. To be eligible, patients must have
incomes below 200 percent of the FPL and be uninsured.35
These programs and others like them have the potential to simplify the pro-
cess considerably, particularly when they can arrange with manufacturers
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to provide bulk supplies of needed drugs instead of the labor-intensive pro-
cess of applying separately for each patient. No systematic evaluation of
these programs has been attempted, but one program that operated under
a California litigation settlement from 1999 to 2003 reported to the court
highly positive reviews from participating clinics. Over four years, this pro-
gram distributed 2.6 million monthly supplies of drugs to indigent patients.
The success of these programs, however, tends to rely on a source of funding
and the energy and creativity of those creating and running the programs.
Points of Access for Multiple Programs
Some recent initiatives have attempted to simplify procedures and to avoid
some of the problems associated with having separate procedures for each
manufacturer’s program.
The manufacturers, working through their trade association (PhRMA),
have sponsored the Partnership for Prescription Assistance. Launched in
April 2005, the Partnership reports having helped over 3 million patients
since its inception.36 As noted above, the program has promoted heavily
through television advertising and other means. Patients can call a toll-
free number or use the program’s Web site (www.pparx.org), where they
enter their income, drug needs, and other information relevant to deter-
mining their qualification for participating programs. They may receive
referrals to any of 180 PAPs operated by manufacturers, as well as 300
other public and private patient assistance programs. The Partnership will
send people applications that are partially completed (or they can print
these off the Web site).37 Manufacturer programs, however, maintain sepa-
rate application forms and separate eligibility requirements. The Partner-
ship was based on other PhRMA-supported state pilots in Wisconsin, New
Mexico, and Georgia, and similar statewide efforts in several other states.
Some nonprofit organizations question PhRMA’s motives and argue that
the same funds could be better spent, especially given the existing efforts
by many such nonprofits to design innovative ways to streamline the pro-
cess of obtaining drugs through manufacturer PAPs. A key question is
whether the Partnership is designed in the best way to help clinics and
other providers, who would benefit by a standardized and simplified ap-
plication form and uniform eligibility requirements. Others have raised con-
cerns that the industry might be “looking for success through marketing
and exposure, more than at the drugs actually delivered to patients.”38
An alternative resource that is not tied to the manufacturers is RxAssist
(www.rxassist.com), a pharmaceutical access information center funded
by foundations, corporate sponsorships, and private donations. It is oper-
ated by Volunteers in Health Care (based in the Brown University Center
for Primary Care and Prevention), a resource center for safety net health
care providers. RxAssist maintains a database of patient assistance pro-
grams as well as other resources for both patients and providers. Like the
Partnership, RxAssist maintains a Web site that helps simplify the
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application process for those seeking to use manufacturer PAPs.39 An-
other resource, NeedyMeds (www.needymeds.com) provides informa-
tion on available programs. This nonprofit organization started when an
Alabama social worker put together a database on PAPs. A family phy-
sician launched the Web site in 1997.40
Manufacturer-Sponsored Discount Cards
Discount cards are available from a variety of sources, including retail
pharmacies, states, and other organizations. About a dozen states have
such programs, and several have shifted focus from seniors to a younger,
uninsured population (see text box for description on state-sponsored dis-
count card programs).
One private-sector discount card was introduced in 2005 by ten manufac-
turers as an alternative to their own PAPs. This joint card, known as the
Together Rx Access card, allows qualifying individuals to pick up mainte-
nance drugs at the pharmacy at a discounted price, whereas many PAPs
State-Sponsored Drug Discount Cards
About a dozen states currently operate discount card programs that
provide a safety net for some residents, including populations un-
der age 65. Several additional programs are available only for se-
niors or disabled Medicare beneficiaries, and several others have
been enacted but are not yet operational. Typically, these programs
are open to individuals below a given income threshold (often be-
tween 200 and 400 percent of the FPL) and without any other source
of drug coverage. Discounts are made available at participating
pharmacies. Maine’s Rx Plus program, for example, is open to any-
one who meets income guidelines and offers discounts from 15 to
60 percent off retail prices for drugs on its preferred drug list. After
Medicare introduced its Part D program, some states that initially
created discount cards for their Medicare-eligible residents have
shifted their focus to under-65 uninsured residents. Although its
program is not yet operational, California in 2006 enacted a law to
provide discounts (leveraging the purchasing power it now uses
for Medicaid) on drug purchases by uninsured low- and moderate-
income residents (those below 300 percent of the FPL or qualifying
based on high medical expenses).
Source: National Conference of State Legislatures, “State Pharmaceutical Assistance Programs,”
updated April 11, 2007, available at www.ncsl.org/programs/health/drugaid.htm; Maine Health and
Human Services, Office of Elder Services, “A Guide to Prescription Drug Assistance in Maine –
November 2005,” available at www.maine.gov/dhhs/beas/medbook.htm; and Office of the Gover-
nor, “Governor Schwarzenegger Signs Legislation to Make Prescription Drugs More Affordable
for Uninsured Californians,” press release, September 29, 2006, available at http://gov.ca.gov/
index.php?/press-release/4159.
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focus on higher-cost drugs and require the person to get the drug at the
physician’s office. Coverage extends to over 300 drugs (mostly brand-
name products) with typical discounts from 25 percent to 40 percent.
But unlike many of the separate PAPs, drugs cannot be obtained free of
charge (though referrals may be made to such programs).41 Individuals
are eligible for the Together Rx Access card if they have incomes no more
than about 300 percent of the FPL, as long as they have no prescription
drug coverage, are not eligible for Medicare, and are U.S. citizens. Eligi-
bility can be determined through an online application, which offers im-
mediate determination of eligibility, or by a mail-in application. Once
obtained, the card can be used at participating pharmacies, which in-
clude a majority of pharmacies across the country. By the end of 2006,
nearly 800,000 people had obtained a card.42
In general, however, discount cards provide only limited assistance to those
with limited means. In particular, indigent patients may not be able to
afford even the discounted price of an expensive drug. A 2002 study spon-
sored by the Kaiser Family Foundation highlighted other issues consum-
ers confront when they try to shop for the discount card program that will
generate the most cost savings for them. Obstacles include lack of stan-
dardization of drug cards’ benefit descriptions, restriction of discounts to
specific drugs only, use of undisclosed prices from which discounts are
derived, inconsistency of prices, and availability of discounts only for mail-
order purchases. In some cases, the discounted price can only be obtained
from a pharmacy in the program’s network, and the availability of that
price varies from store to store and over time.43
PAPs for Generic Drugs
Most manufacturer PAPs provide only brand-name drugs within the pe-
riod of patent protection. On the one hand, this means they provide access
to the most expensive drugs, while patients may be able to afford needed
generic drugs without assistance. Many generic drugs are relatively inex-
pensive (often under $5 for a one-month supply), so the need for help in
obtaining them is less than for brand-name drugs. Recent initiatives by
large pharmacy retailers such as Wal-Mart, Kmart, and Target have helped
to guarantee low prices for at least some generic drugs. But some generic
drugs can be quite expensive, including some specialty drugs and some
newly approved generics (such as those in the six-month period when
one manufacturer has exclusivity for its generic version after the origina-
tor drug has gone off patent).44
Furthermore, in drug classes that include both generic and brand-name
options, the availability of free brand-name drugs through PAPs may
encourage their use when a generic alternative may be preferable for a
particular patient. Also, if the patient loses eligibility for the free drug,
there could be complications in switching at that time to the cheaper
generic option.
Most manufacturer
PAPs provide only
brand-name drugs
within the period of
patent protection.
Background Paper
May 9, 2007
National Health Policy Forum  |  www.nhpf.org 14
Two relatively new programs have improved access to generics at reduced
prices. These programs represent limited attempts to provide the same
help that manufacturers provide for brand-name drugs.
In the fall of 2004, Rx Outreach was launched by Express Scripts, one of
the largest pharmacy benefit managers in the United States. The
program’s Web site reports that the program was inspired by an Express
Scripts employee who witnessed a family member’s struggle to pay for
medications. This generic PAP offers about 120 generic drugs to indi-
viduals with household incomes below 250 percent of the FPL. There is
no restriction based on either the patient’s age or eligibility for other
programs. Patients pay either $20 or $30 (depending on the drug) for a
three-month prescription, and the drugs can be sent to patients’ homes,
clinics, or other providers.45
Xubex Pharmaceutical Services offers a similar program that makes avail-
able about 250 generic drugs. For a 90-day supply, the patient is charged
$20 to $30, plus a $3.95 shipping and handling fee, for each order. Like Rx
Outreach, eligibility requires an income below 250 percent of the FPL. With
this program, however, those with insurance coverage (other than enroll-
ment in Medicare Part D) are not eligible. Unlike Rx Outreach, proof of
income (for example, a pay stub) is required.46
Both programs offer many of the most commonly prescribed generic
drugs. Because the drugs offered by these two programs are not free, it
is unclear how much benefit they offer. The cost of obtaining some of
these drugs may be little better than purchasing them from retail phar-
macies, especially as the competition over generic drug pricing has
become more intense. For example, a 90-supply through Wal-Mart’s
program would cost $12 compared to $20 for most drugs through these
two programs. But Rx Outreach and Xubex include some drugs not
available in Wal-Mart’s new program, such as simvastatin (generic
Zocor) and sertraline (generic Zoloft), both commonly prescribed drugs
that went off patent in 2006. In addition, many of the safety net provid-
ers that help patients obtain drugs may have access to better prices
through the 340B program (below).
Changes in Manufacturer PAPs as a Result of Medicare Part D
Before the implementation of Medicare Part D, many seniors used manu-
facturer PAPs to obtain drugs they could not afford to purchase. Under
Part D, the poorest beneficiaries qualify for that program’s low-income
subsidy. Subsidy-eligible beneficiaries are relieved of most cost sharing,
including the need to pay for the full cost of drugs if they reach the cover-
age gap (often referred to as the donut hole). But for those enrolling in
Part D but not qualifying for the subsidy, out-of-pocket costs can remain
substantial. Some individuals anticipated that they would be able to con-
tinue obtaining free or reduced-cost drugs through PAPs while in the cov-
erage gap (or to avoid high cost sharing for some expensive drugs).
Background Paper
May 9, 2007
National Health Policy Forum  |  www.nhpf.org 15
The Medicare Modernization Act of 2003 (MMA), however, does not count
most purchases made by third parties toward the true out-of-pocket
(TrOOP) spending threshold that qualifies beneficiaries for catastrophic
coverage.47 This policy was reiterated in 2005 when the Office of the In-
spector General (OIG) of the Department of Health and Human Services
(HHS) ruled that the unpaid value of drugs provided by a manufacturer’s
PAP, such as when the beneficiary is in the coverage gap, does not count
towards TrOOP. The OIG’s ruling suggested that drug purchases subsidized
by manufacturer PAPs present risks under the anti-kickback statute. The
general idea is that providing costly drugs to the patient (for example, in the
coverage gap) increases the likelihood of federal payments that benefit the
manufacturer (for example, payment for the same drug once the benefi-
ciary becomes eligible for catastrophic coverage). There is no legal penalty
to the beneficiary, but the manufacturers must ensure that they are not pro-
viding drugs to Part D enrollees.48
Not all beneficiaries are affected the same way by the ruling against these
programs. For example, a beneficiary whose costs will exceed the cata-
strophic threshold as a result of purchasing drugs not available through
these programs will still spend $3,850 out of pocket before qualifying for
catastrophic coverage (and then only about 5 percent cost sharing for ad-
ditional drug purchases). By contrast, a beneficiary with only minimal costs
beyond the drug previously obtained for free from a manufacturer pro-
gram might have avoided ever reaching the gap with the PAP still in place,
resulting in much lower overall out-of-pocket costs.
The OIG’s ruling left manufacturers the option of continuing to make their
PAPs available for beneficiaries not enrolled in Part D or those not eligible
for Medicare. But most manufacturers realized that their PAPs would have
to change. The OIG offered several alternatives:
■ Independent Charity PAPs — A manufacturer can make donations to
an independent charitable organization. But it cannot exercise control
over the organization, nor base its donations on the amount of its drugs
dispensed, and the charity must award assistance without regard to
the manufacturer’s interests.
■ PAPs Operating Outside Part D — A manufacturer’s PAP may pro-
vide drugs to beneficiaries enrolled in Part D as long as the drugs are
provided completely outside the Part D benefit. Thus, for example,
provision of the drugs cannot be contingent on a beneficiary’s status
relative to the coverage gap, and the value of purchases cannot count
toward TrOOP. For example, a PAP could provide an expensive drug
throughout the year. The beneficiary’s Part D plan would provide all
other drugs as if the expensive drug in question did not exist.
■ Coalition Model PAPs — A group of manufacturers might create a
PAP. To be allowed, such a PAP would have to involve a large number
of manufacturers, include all drugs made by each participating manu-
facturer, and have a system by which no particular drug is favored.49
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According to a compilation by RxAssist in January 2007, manufacturers
have responded in a number of ways. Some (24) closed their PAPs to all
Medicare beneficiaries, while others (38 programs, including Bristol-
Myers-Squibb, one of the largest manufacturers) restricted their programs
to Medicare patients not enrolled in Part D. A few of these plans allow
Medicare Part D enrollees to apply for selected medications only (for
example, Enbrel, Zyprexa, or Prevacid), consistent with the second OIG
alternative. Another set of manufacturers (19 programs, including most
of the largest companies) allow all Medicare beneficiaries to apply—again
consistent with the OIG rules—although they may be required to dem-
onstrate financial hardship.50
For example, Medicare beneficiaries who use Novartis transplant or on-
cology products (drugs that are normally covered under Medicare Part B
rather than Part D) and who enroll in a Part D plan may continue to re-
ceive help through the Novartis PAP for those drugs as long as they con-
tinue to meet eligibility criteria for the PAP, do not qualify for the Part D
low-income subsidy, and show financial hardship in affording their medi-
cations despite the Part D benefit coverage. Patients using other Novartis
products are evaluated on the basis of individual circumstances, includ-
ing their degree of financial hardship. In all cases, the value of the drugs
received would not count toward TrOOP.51
Similarly, Pfizer expanded its program’s eligibility policy so that people
with insurance, including Medicare beneficiaries with Part D coverage,
can get access if facing financial or medical hardship. After the Connec-
tion to Care program reviews the initial application to see if the patient
meets the income requirement (household income at or below 200 percent
of the FPL, with verification through a tax return) but has insurance cov-
erage for their Pfizer drugs, they are sent a Hardship Exception Request
Form. Once the patient and physician complete and sign that form, the
program determines whether the patient is eligible to receive the requested
drugs without charge. If approved, a three-month supply of the drug is
typically shipped to the physician’s office.52
GlaxoSmithKline introduced a new program for 2007. GSK Access pro-
vides free medications to eligible Part D enrollees after they spend at
least $600 of their own money on outpatient drugs. The same people are
also eligible for oncology medicines through an existing PAP. Eligibility
requires an income below 250 percent of the FPL (or 350 percent for the
oncology program). Medicare beneficiaries not enrolled in a Part D plan
and not eligible for the Part D income-based subsidy would qualify for
GlaxoSmithKline’s existing PAP.
The short-term result of Part D implementation is that existing arrange-
ments for some Medicare beneficiaries were disrupted. Some programs
that supported patients’ coinsurance for physician-administered drugs
covered under Part B were, at least for a time, made unavailable to Medi-
care beneficiaries, and anecdotal evidence suggests an adverse effect for
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at least some beneficiaries and the physicians who administer these drugs.
The situation continues to evolve as manufacturers revamp their program
rules. For Part D drugs, beneficiaries eligible for the low-income subsidies
generally no longer need the help of the PAPs as they enroll in a Part D
plan. Beneficiaries not eligible for the subsidy but requiring help with cost
sharing in the initial coverage period or with the cost of drugs in the cov-
erage gap may be confused about their eligibility for PAPs. Many manu-
facturer programs invite applications from those with financial hardship,
but at least two manufacturers were quoted in a recent trade newsletter as
saying that enrollment from Part D enrollees was lower than expected.53
THE FEDERAL 340B PROGRAM
Access to prescription drugs for uninsured individuals is always preceded
by the need to see a physician or other provider who can write a prescrip-
tion for the drug needed. Just as prescribers most often provide the point
of access between the patient and manufacturer PAPs, many safety net
providers also operate pharmacies that can obtain drugs and make them
available to patients. The federal 340B program, established in the Veter-
ans Health Care Act of 1992, offers a
means by which these safety net pro-
viders can obtain drugs at a low price
and stretch their resources. People
without drug coverage may then be
able to get their prescriptions filled ei-
ther free of charge or at a reduced price,
depending on the policies in force at
the safety net clinic or hospital.
The 340B program places a ceiling on
the price paid to manufacturers for pre-
scription drugs when sold to certain
safety net providers (see next section
for how prices are established). The
12,000 entities that participate in the
program include federally qualified
health centers (FQHCs),54 hemophilia
treatment centers, Ryan White pro-
grams, sexually transmitted disease
and tuberculosis programs, Title X fam-
ily planning clinics, urban/638 tribal
programs, and certain disproportion-
ate share hospitals. About one-third of
eligible providers are family planning clinics and one-fourth are FQHCs
(Figure 3). The Ryan White AIDS Drug Assistance Programs (ADAPs),
created to help improve access to drugs for those with HIV or AIDS, also
benefit from the discounted prices made available under the 340B pro-
gram (see text box, next page).
FIGURE 3
Distribution of Covered Sites in the 340B Program,
by Type of Entity, Quarter 2, 2007
Source:  2007 Quarter 2 Statistics for 340B Covered Entities Number of Registered Covered
Entity Sites by Entity Type, April 2, 2007, p. 2; available at ftp://ftp.hrsa.gov/bphc/pdf/opa/
Stats_2007_QTR_2.pdf.
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The 340B program is administered by the Health Resources and Services
Administration (HRSA), an agency of the U.S. Department of Health and
Human Services. Eligible entities must enroll with HRSA, after which they
are added to a list of eligible entities. Manufacturers and wholesalers are
supposed to make the 340B prices available to the all entities on HRSA’s
list.55 HRSA estimates that annual purchasing volume for the program as
a whole was about $4 billion,56 an amount similar to that provided through
manufacturer PAPs.57
For those without drug coverage, these safety net institutions tend to be key
sources for obtaining drugs. In particular, FQHCs and other federally funded
clinics are a major source of primary care services for many uninsured
All 50 States, the District of Columbia, and the ter-
ritories receive ADAP grants, which are calculated
based on their proportion of the nation’s living
AIDS cases. Some programs also receive funds
from state general revenues, other parts of the Ryan
White CARE Act, or drug manufacturer rebates.
Each state and territory determines its own eligi-
bility criteria, although participants must be medi-
cally diagnosed with HIV and considered “low
income.” Some states require a specific CD4+ count
(a test measuring the strength of a patient’s im-
mune system) for participation. Each state also de-
termines the drugs included in its ADAP formu-
lary, within the limits of the federal minimum, and
how those medications are distributed. Some use
a pharmacy reimbursement model like that of
Medicaid, in which participating pharmacies bill
ADAP for drugs dispensed to ADAP clients and
then receive a rebate from the manufacturer to
achieve the guaranteed 340B discount. Others pur-
chase drugs themselves at the discounted price and
mail them directly to clients, or distribute medica-
tions through public health clinic pharmacies. The
high cost of the most effective HIV medications,
the decline in AIDS mortality, and the steady rate
of new HIV infections suggest that demand for
ADAP services is likely to increase.
AIDS Drug Assistance Programs (ADAPs) are au-
thorized by the Ryan White Comprehensive AIDS
Resources Emergency (CARE) Act, which was en-
acted in 1990 to provide medical and support ser-
vices to persons with HIV and AIDS who lacked
adequate health insurance. ADAPs provide medi-
cations for HIV treatment and may also provide
assistance toward other heath care services, includ-
ing health insurance for eligible clients. When ADAP
was reauthorized in 2000, Congress included a
supplemental program to help states expand HIV
treatment to persons with incomes below 200 per-
cent of the FPL. States must contribute one out of
every four federal dollars in this supplemental pro-
gram, and an ADAP’s funds may only be used to-
wards the purchase of HIV medications. Overall,
ADAPs have approximately 142,000 participants
(about one-fourth of those with HIV/AIDS); more
than 80 percent of participants have incomes at or
below 200 percent of the FPL, and two-thirds are
African American or Hispanic. The program was
reauthorized again in 2006 and changes include a
new formula for state awards and a new minimum
drug formulary. In 2006, estimated spending on
drugs and insurance benefits by ADAPs was $1.2
billion, and the average client was estimated to re-
ceive support of about $12,000 in drug costs.
Source: Health Resources and Services Administration, “Title II: AIDS Drug Assistance Program,” available at http://hab.hrsa.gov/programs/adap;
Jessamy Taylor, “The Basics: The Ryan White CARE Act,” National Health Policy Forum, September 14, 2005, available at www.nhpf.org/pdfs_basics/
Basics_RyanWhite.pdf; and Jennifer Kates et al., “National ADAP Monitoring Project Annual Report: Summary and Detailed Findings,” National
Alliance of State and Territorial AIDS Directors and the Henry J. Kaiser Family Foundation, April 2007, available at www.kff.org/hivaids/7619.cfm.
AIDS Drug Assistance Programs
Background Paper
May 9, 2007
National Health Policy Forum  |  www.nhpf.org 19
Americans. Community health centers serve one in eight of those lacking
insurance and one in five of low-income Americans without insurance.58
The 340B program is also important for many safety net hospitals—
specifically those qualifying as a disproportionate share hospital (DSH).
These include government-owned or government-operated facilities as
well as other nonprofit hospitals that have relationships with state or local
governments to serve low-income patients. These hospitals must also
have a Medicare disproportionate-share adjustment percentage over 11.75
percent, thus qualifying under Medicare’s rules as serving a higher-than-
average number of uninsured or under-insured patients in comparison
to other hospitals. The MMA made further changes to these rules so that
about 800 more hospitals—mostly rural and small urban hospitals—now
meet the DSH requirements for 340B eligibility.59 In addition, more pri-
vate nonprofit hospitals with local or state government contracts have
started to participate in recent years.
Eligibility can be important for these qualifying hospitals in terms of
purchases of outpatient drugs. They are particularly important for ser-
vices provided in emergency departments, outpatient oncology and sur-
gery departments, cardiac clinics, and other outpatient clinics. The lower
prices for drugs in many of these settings benefit uninsured patients in-
directly in that they reduce the cost to the hospital of treating these pa-
tients and, presumably, increase their willingness to take patients who
are unable to pay. They may also reduce the charges made to these pa-
tients, some of whom attempt to pay. In addition, some hospitals oper-
ate outpatient clinics that make prescriptions available to patients for
free or at reduced prices.
Although it is common for hospitals to get these discounts for drugs dis-
pensed through their outpatient clinics, manufacturers are not required to
participate for inpatient drug purchases. The MMA attempted to encour-
age more participation for inpatient drug purchases by removing one po-
tential disincentive for manufacturers to extend deals in this setting.60 Still,
according to the organization Safety Net Hospitals for Pharmaceutical
Access, hospitals are obtaining discounts on only about 12 percent of com-
monly used brand-name drugs for their inpatient services. Legislation [The
Safety Net Inpatient Drug Affordability Act, introduced by Senators Thune
(R-SD) and Bingaman (D-NM) and Representatives Emerson (R-MO) and
Rush (D-IL)] was considered, but not passed, by the 109th Congress to
extend the 340B program to inpatient settings. A potential effect of this
legislation would be to reduce the costs to qualifying hospitals of caring
for uninsured and under-insured patients.61
Prices Available Through the 340B Program
The advantage for safety net providers that participate in the 340B pro-
gram is that they get access to drugs at far more favorable prices than are
otherwise available to them in the marketplace. Under the terms of the
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Veterans Health Care Act of 1992, manufacturers must make these drugs
available at a discounted price as a condition of eligibility for Medicaid
reimbursement. The amount of the discount follows the same formula
used in the Medicaid program, and covered entities may negotiate dis-
counts that are even greater than those obtained by Medicaid programs.
Prices obtained through the 340B program are esti-
mated to be about half of the “list price” paid by
retail customers without access to any discounts.
These prices are between 50 and 80 percent of the
typical post-rebate price paid by private insurers.62
Drug sales through the 340B program are subject
to two key restrictions. One prevents resale of dis-
counted drugs to anyone other than a patient of
the participating entity. This anti-diversion rule protects manufacturers
from situations where clinics, hospitals, or other participating facilities
would make discounted drugs available to a broader array of patients.
The second restriction ensures that manufacturers do not pay a Medicaid
rebate for the same drug purchases that are made at 340B-discounted prices,
that is, purchasers do not get more than one discount.
Further discounts below those available to all 340B entities can be obtained
through the Prime Vendor Program, which operates under contract to the
federal government. HealthCare Purchasing Partners International (HPPI),
a group purchasing organization based in Texas, holds the current con-
tract. HPPI has the ability to negotiate prices below the statutorily required
prices as well as offer more favorable distribution arrangements for those
entities that choose to participate in this program. The Prime Vendor Pro-
gram also makes some other health care products available, including
vaccines, diabetic meters, and test strips. At present, HPPI represents about
one-third of the 340B-covered entities purchasing $2.2 billion in drugs each
year, and it uses this volume as leverage to negotiate discounts.63 The pro-
gram achieves an added discount of 11.6 percent on about 2,700 items.
Despite the general success of the 340B program in providing access to
low drug prices, there are some concerns that participating providers do
not always get the low prices to which they are entitled. The HHS OIG has
reported several times recently on this program. An October 2005 study
suggested that HRSA fails to oversee the program adequately by not al-
ways verifying that entities receive the low prices to which they are entitled.
Specifically, it found that the government’s price files lack over one-fourth
of the prices needed to verify that participating entities can obtain the
discounts they are supposed to receive. It also found that neither HRSA
nor the participating entities had the ability to verify that they received
the appropriate discounts.64 A subsequent OIG study, released in July 2006,
compared actual prices paid by 340B entities to the ceiling prices. About
14 percent of total purchases exceeded the ceiling prices, resulting in over-
payments. These overpayments were most likely to occur for low-volume
entities and for low-cost drugs.65
Prices obtained through the 340B pro-
gram are estimated to be about half of
the “list price” paid by retail customers
without access to any discounts.
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Problems Affecting the 340B Program
and Potential Improvements
Despite the value of the 340B program, not all eligible entities actually
participate in it. According to a survey of eligible entities conducted for
HRSA, only 63.5 percent of 588 surveyed entities reported that they were
participating.66 The study also found significant discrepancies between
those listed as participants on the government’s Web site and those actu-
ally saying that they participated. Among the nonparticipating entities,
about 40 percent indicated that they did not understand the 340B pro-
gram “at all” while another 30 percent understood it “only slightly.”
Among the barriers cited by eligible entities that might consider using the
340B program are high startup costs, the complexity of the required
recordkeeping, the confusing nature of the program, and the perceived
absence of adequate information about the program.67 Some eligible enti-
ties even indicated that they had not heard of the program at all.
There have been several efforts to encourage more eligible entities to join
the 340B program and to make its use easier. Extensive guidance is avail-
able through The Bridge to 340B Comprehensive Pharmacy Solutions in
Underserved Populations, a guidebook prepared by Medicine for People in
Need (Medpin) with support from HRSA’s Pharmacy Services Support
Center. Medpin, a program of the nonprofit California-based Public Health
Institute and supported by several foundations in that state, works with
safety net providers to improve access to medications. It makes this step-
by-step guide available at no charge to safety net providers, especially
community health centers and other clinics. It provides descriptions of
various models for participating in the 340B program and offers key points
of advice designed to encourage participation.68
Another barrier cited by some health center administrators is the absence
of a pharmacy. In general, eligible organizations must have some means
of dispensing the drugs they purchase through the 340B program. Typi-
cally, they operate under one of three models: owning and operating an
in-house pharmacy, contracting with a retail or mail-order pharmacy where
the entity purchases the drugs but uses a contractor to provide the phar-
macy services, or employing physicians or other providers who are li-
censed to dispense the drugs but do not operate an actual pharmacy. In
the latter model, which may vary based on state law, the health center or
other entity would own the drugs and assume fiscal responsibility for
operating and dispensing costs.
Since 2001, HRSA has encouraged innovation by allowing several efforts
on a demonstration basis to build on the 340B program to expand its reach
to more people. There are about 20 such projects in operation, most of
which involve getting more community health centers linked to the pro-
gram. These demonstrations are important because many small clinics,
especially in rural areas, lack the resources to operate a pharmacy. HRSA
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is currently developing a regulatory notice that would allow some arrange-
ments that have been used through demonstrations.
There are at least three different arrangements being used, many of which
offer solutions to the current rules requiring that each site have some type
of pharmacy setup on location. Perhaps the most common is to develop a
network of covered entities that can share a common pharmacy. For ex-
ample, a program in Spokane, Washington, uses “remote dispensing tech-
nology” to allow pharmacists at one health center to dispense drugs at
remote health clinics. When necessary, patients receive counseling through
video-conferencing. Similarly, Georgia’s Columbus Regional Community
Healthcare Network links a local safety net hospital to two local health
centers. The hospital provides the pharmacy services, including pharma-
cists to work with the physicians and nurses at the clinics.69
Several of the demonstration projects fo-
cused on the delivery of care for diabetes.
The goal was to show positive results in
terms of management of the disease, get-
ting patients access to pharmacists, and re-
taining their patients for at least 12 months. One health center in Tucson
focused on services to Spanish-speaking and Native American people.
Arizona state law was modified to allow pharmacists to initiate and
modify medications consistent with written protocols approved by phy-
sicians. This use of collaborative drug therapy management allowed the
pharmacist to monitor the patients, provide diabetes education, and make
sure they received the needed drugs. Participating patients were able to
lower their blood glucose, blood pressure, and cholesterol levels. Simi-
lar results were attained in other communities that also relied extensively
on pharmacists or nurses.70
Other resources available to eligible clinics include groups that work with
pharmaceutical wholesalers to negotiate better prices for safety net pro-
viders, in addition to the Prime Vendor program described above. Soon
after the 340B program was created, the Texas Association of Community
Health Centers created the “340Better” program. Its purpose was to use
the combined purchasing leverage of participating community health cen-
ters to improve the distribution of drugs obtained through the 340B pro-
gram and to obtain even deeper discounts. The participating clinics have
representatives serve on a collective Pharmaceuticals and Therapeutics
(P&T) Committee to determine which high-cost drugs are dispensed most
frequently. On the basis of this determination, the program has been able
to negotiate discounts that average at least 15 percent below the 340B ceil-
ing price. The program was expanded nationwide in 1997 and now works
with a wholesaler (Cardinal Health) to serve nearly 400 community health
centers from 37 states.71
Although many of the ideas described here have the potential to enroll a
higher percentage of the eligible entities into the 340B program, the ulti-
mate limitation of this approach is the uneven distribution of safety net
HRSA has encouraged innovation through
demonstration projects to expand the reach
of the 340B program.
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providers in the United States.72 Some communities (for example, Boston,
Massachusetts) have a wide array of community health centers—both fed-
eral qualified health centers and other comprehensive primary care pro-
viders that do not meet FQHC qualifications. But other communities (such
as Little Rock, Arkansas) have few organized health centers of any type.
In some cases, these communities may have free clinics that operate on a
limited schedule and with volunteer physicians and nurses. The latter,
however, are unlikely to qualify for participation in the 340B program even
in partnership arrangements.
PHYSICIANS’ ROLE IN HELPING
PATIENTS WITHOUT DRUG COVERAGE
Physicians are not always aware of the challenges that drug costs im-
pose on their patients’ ability to comply with their prescription orders.
But when they are aware, physicians have some ability to help their pa-
tients beyond connecting them to manufacturer PAPs or other safety net
programs. Physicians may be able to make sample drugs available to
their uninsured patients or to prescribe less expensive drugs.
Drug Samples as a Source of Medications
When a patient without drug coverage is fortunate enough to have a regular
physician, that physician may use manufacturer-supplied samples as a
way to help by provide a supply of drugs. The patient may receive enough
drugs for the entire course of treatment, or at least enough to get started.
In some cases, a small supply may provide the patient time to get enrolled
with a manufacturer PAP or some other means of receiving needed drugs.
Most pharmaceutical manufacturers provide samples, especially for their
newer brand-name drugs. Physicians may use samples for a variety of
reasons, including making them available to patients who cannot afford
to pay for the particular drug. Samples may also be used for patients who do
not qualify for any appropriate manufacturer PAPs or public programs or for
patients who are waiting for their medications to arrive from the PAP.
Estimates of the volume and frequency with which samples are used for
uninsured or other low-income patients are difficult to obtain. Manufac-
turers made available to doctors about $16 billion worth of sample drugs
in 2004, more than the estimated total value of drugs distributed by PAPs
and through the 340B program.73 But this total represents the retail value
of all drugs received by doctors and thus includes those given to insured
patients for convenience and those never distributed to patients. Accord-
ing to a 2001 national survey of physicians, 92 percent of physicians said
they had accepted free samples from a drug industry representative, and
a 2003–2004 survey of physicians in six specialties found that 78 percent
reporting receiving samples.74 One study of 18 practices in Nebraska found
that samples were used in about 20 percent of all patient encounters.
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Samples were used for different circumstances, ranging from starter dos-
ages to complete courses of antibiotics, to several months’ supply of some
drugs, and physicians attributed use to a variety of motives that included
temporary relief or convenience, testing for efficacy or tolerability, as well
as cost concerns.75
In one recent study of obstetrician-gynecologists, physicians were asked
about the ethics of various scenarios. Nearly all (92 percent) agreed that it
was ethically proper to accept free samples of a new drug from a pharma-
ceutical manufacturer’s representative, and most in fact had such samples
and said that they distributed them to patients. The most common reason
cited for distributing such samples was the patient’s financial need (cited
by over 90 percent of surveyed physicians as one of multiple reasons).
One-third said that accepting samples would influence their decision to
prescribe drugs they received as samples.76 In two other studies, just over
one-half of physicians thought that samples influenced their prescribing.77
The use of samples raises both practical and ethical issues. Federal law re-
quires providers to document in the chart when patients receive sample
medications.78 But it may be difficult to inventory all samples and report
overall usage. Some medications require temperature-controlled storage,
but finding such storage can be a problem for some physician offices. Fur-
thermore, sample medications may not be adequately labeled when dis-
pensed or may not contain dosing instructions and warnings of possible
side effects. Typically, they are not available in childproof packaging. Al-
though some providers may provide warnings or appropriate packaging
for patients, as well as check for drug-drug and drug-disease interactions,
this practice is not universal. Because of the difficulty in conducting inven-
tory on and storing samples properly, such medications are at risk of expir-
ing without notice or losing potency. In some states (for example, Florida),
samples cannot simply be discarded when expired; thus, clinics must incur
the cost of contracting with a disposal company to handle expired drugs.79
The use of samples for uninsured patients also raises some ethical concerns.
In their ethical codes, some physician groups address personal use and the
effect of samples on drug selection but do not ban the use of samples.80
Recently, however, some institutions, including the University of Michigan,
the University of Pennsylvania, and Stanford University, have adopted com-
plete or partial bans on drug samples. Because some physicians were con-
cerned about the effect on indigent patients, the University of Pennsylvania’s
hospital instituted a program where patients get vouchers for medications
instead of samples, and the hospital planned to make available free generic
samples at primary care offices. Through this approach, the use of detailing
(marketing to doctors by manufacturer representatives) might be reduced,
and thus so might the influence on doctors’ prescription choices.81 Instead
of a ban on the use of samples, one California clinic systematized its process
for receiving and storing samples by instituting a drug sample formulary
and an electronic coding system. Emphasis was placed on using samples
The use of samples
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for acute drug needs (for example, antibiotics) rather than medications
for chronic illnesses. Storage was based on an electronic system, and
samples were dispensed with labels and patient instructions similar to
regular pharmacy dispensing.82
Concerns about the use of samples have also been addressed in a report for
the California Healthcare Foundation by John Piette, who argues that
samples, while useful in the short term, may increase costs in the long run.
His logic is that samples encourage both the prescribing of brand-name drugs
instead of cheaper generic alternatives and the use of treatments of limited
clinical value. He also argues that the use of free samples tends to increase
the cost of promotion of products by manufacturer representatives and thus
inflates the overall cost of health care.83 The approach of providing vouch-
ers to uninsured patients would not necessarily address these concerns un-
less there was a mechanism for including generic drugs.
Changes in Prescribing Behavior
Physicians may also consider reducing drug costs for their patients with-
out drug coverage by shifting their thinking about which drugs to pre-
scribe or by offering other alternatives. That is, if the goal is for doctors to
find less costly treatment alternatives that their patients can afford, part of
the solution might be to change the awareness of providers about less
costly approaches to drug treatments. First, physicians and other provid-
ers would need to identify that their patients in fact require assistance to
obtain prescribed drugs. Studies have shown that clinicians typically do
not discuss cost-related issues with their patients.84 According to two stud-
ies, between 30 and 40 percent of patients who reported cutting back on
the use of drugs for reasons of cost informed their doctor or nurse in ad-
vance of doing so.85 While there are legitimate barriers for both the clini-
cian and the patient that make it a challenge to have these conversations,
they must occur if physicians are to offer help.86 Physicians also tend to be
unaware of the cost of drugs—both the absolute cost of the medications
for those without insurance coverage and the typical cost-sharing amounts
for those with coverage.87
Some available steps for a clinician to suggest, apart from offering access to
relevant safety net programs, include minimizing prescriptions for drugs
that are not truly necessary (especially for patients with multiple health con-
ditions), increasing the effective use of generic drugs, considering less costly
therapeutic alternatives, and physically splitting pills in cases where a pill’s
full dose is not necessary.88 One might argue that some of these steps should
always be part of good patient care, but they take on added importance for
patients who may skip taking medications they cannot afford to purchase.
Generic substitution and therapeutic substitution may be required by
health plans for their insured patients, but such methods can be even
more valuable for uninsured patients. Uninsured patients do not face
the insurer’s electronic edit at the pharmacy counter that imposes the
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substitution (although some state laws do require generic substitution).
So if uninsured patients are not savvy about asking for less expensive
alternatives, they must rely on physicians or pharmacists to suggest ap-
propriate substitutes. Sometimes neither the physician nor the patient is
aware of the potential for lower costs.89 Physicians may also be concerned
that they are not practicing good medicine if they switch patients to a less
expensive medicine. But according to one family physician, “it is necessary
to redefine the practice of ‘best medicine’ to include helping patients bal-
ance their drug costs with benefits. While new, expensive drugs may offer
greater benefits for some patients, they may not offer those improved ben-
efits for all patients. By helping patients use medications cost-effectively,
physicians can help keep medications affordable for everyone.”90
Similarly, pill splitting is not often suggested by physicians, some of whom
have concerns that not all pills can be split easily or safely. Nevertheless,
studies have suggested the safety of this approach.91
CONCLUSION
The safety net that helps uninsured patients get access to medications
relies on a mix of public and private components. Manufacturers create
part of the safety net through their provision of free drugs and by mak-
ing drug samples available to prescribers, while the federal government
uses its leverage to obtain reduced prices for qualifying providers in the
340B program. Some other players in system, including pharmacy ben-
efit managers, retail pharmacies, and health plans, play a role as well
when they sponsor discount cards or price certain drugs at affordable
levels. But in the end, uninsured patients face a fragmented safety net
system for prescription drugs that can require considerable effort and
determination to administer.
In the absence of coverage expansions that would increase access to a full
array of health services, including prescription drugs, federal or state
policymakers might consider an expanded role for pharmacy assistance
programs, discount cards, or other discounted pricing arrangements for
the general uninsured population. Some elderly or disabled beneficiaries
receiving benefits from these state programs are now getting some of their
drugs through Medicare Part D coverage. To the extent that states operat-
ing such arrangements achieve savings, they may consider making these
programs available to broader low-income populations.
Policymakers may also consider incremental changes to address the effi-
ciency of the manufacturer PAPs or the federal 340B program. For example,
standardized application forms and simplified eligibility requirements for
the manufacturer PAPs might help more uninsured patients access these
programs to obtain more of their drugs. Pharmaceutical manufacturers
could take such steps on their own, or policymakers could identify a
mechanism or incentives to encourage such steps. Because generic drugs
are generally unavailable through these programs, policymakers might
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want to seek innovative ways to make generic drugs more accessible to
low-income uninsured populations.
Although the 340B program is successful in making prescription drugs
available to safety net providers at discounted prices, recent studies by
the HHS OIG have identified gaps in enrolling all eligible providers and
ensuring that providers always get the correct prices. Policymakers may
want to consider ways of replicating some of the innovative ideas that
been tested in the HRSA demonstrations, as well as testing other ap-
proaches to expanding and strengthening the 340B program.
Prescription drugs can be a lifeline in keeping a patient’s diabetes or asthma
in check, controlling hypertension, or limiting cholesterol levels. But fill-
ing prescriptions may be beyond the means of many persons without drug
coverage. The safety net today includes valuable resources to help these
individuals get the drugs they need. Policy measures that fill the gaps in
the current safety net have the potential to make a significant difference
for patients with limited resources.
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